Table 3.
Clinicopathological Correlation of the Percentage of Pre-S2 Plus Pre-S1+Pre-S2 Deletions in 40 HBV-Related HCC Patients
| Characteristicsa | Low (No. of Patients (%)) | High (No. of Patients (%))b | P-valuec |
|---|---|---|---|
| Density of PD-1-positive cellsd | 25 (100) | 15 (100) | |
| high | 13 (52) | 6 (40) | 0.1983 |
| low | 12 (48) | 9 (60) | |
| Density of PD-L1-positive cellse | 25 (100) | 15 (100) | |
| high | 5 (20) | 15 (100) | <0.0001*** |
| low | 20 (80) | 0 (0) | |
| Age (years) | 25 (100) | 15 (100) | |
| >50 | 22 (88) | 7 (47) | 0.0064** |
| ≤50 | 3 (12) | 8 (53) | |
| Gender | 25 (100) | 15 (100) | |
| men | 21 (84) | 13 (87) | 0.3460 |
| women | 4 (16) | 2 (13) | |
| Smoking | 25 (100) | 15 (100) | |
| yes | 10 (40) | 4 (27) | 0.1923 |
| no | 15 (60) | 11 (73) | |
| Alcohol | 25 (100) | 15 (100) | |
| yes | 5 (20) | 4 (27) | 0.2652 |
| no | 20 (80) | 11 (73) | |
| HBsAgf | 22 (100) | 14 (100) | |
| positive | 22 (100) | 14 (100) | |
| negative | 0 (0) | 0 (0) | |
| HBeAg | 25 (100) | 15 (100) | |
| positive negative |
3 (12) 22 (88) |
3 (20) 12 (80) |
0.2726 |
| HBV genotype | 25 (100) | 15 (100) | |
| B | 19 (76) | 12 (80) | 0.2947 |
| C | 6 (24) | 3 (20) | |
| HBV DNA (copies/mL) | 24 (100) | 12 (100) | |
| >1×104 | 16 (46) | 8 (50) | 0.2909 |
| ≤1×104 | 8 (54) | 4 (50) | |
| Albumin (g/dL) | 25 (100) | 15 (100) | 0.2296 |
| >3.8 | 12 (48) | 6 (40) | |
| ≤3.8 | 13 (52) | 9 (60) | |
| AST (U/L) | 25 (100) | 15 (100) | |
| >34 | 21 (84) | 11 (73) | 0.2245 |
| ≤34 | 4 (16) | 4 (27) | |
| ALT (U/L) | 25 (100) | 15 (100) | |
| >40 | 15 (60) | 11 (73) | 0.1923 |
| ≤40 | 10 (40) | 4 (27) | |
| AFP (ng/mL) | 25 (100) | 15 (100) | |
| >400 | 8 (32) | 7 (47) | 0.1730 |
| ≤400 | 17 (68) | 8 (53) | |
| Tumor size (cm) | 25 (100) | 15 (100) | |
| >5 | 9 (36) | 5 (33) | 0.2644 |
| ≤5 | 16 (64) | 10 (67) | |
| Tumor encapsulation | 25 (100) | 15 (100) | |
| yes | 21 (84) | 9 (60) | 0.1195 |
| no | 4 (16) | 5 (40) | |
| Satellite nodule | 25 (100) | 15 (100) | |
| yes | 2 (8) | 5 (33) | 0.0483* |
| no | 23 (92) | 10 (67) | |
| Lymph node involvement | 25 (100) | 15 (100) | |
| yes | 6 (24) | 0 (0) | 0.0461* |
| no | 19 (76) | 15 (100) | |
| Portal vein thrombosis | 25 (100) | 15 (100) | |
| yes | 1 (4) | 0 (0) | 0.6250 |
| no | 24 (96) | 15 (100) | |
| Vascular invasion | 25 (100) | 15 (100) | |
| yes | 9 (36) | 9 (60) | 0.0902 |
| no | 16 (64) | 6 (40) | |
| Distant metastasis | 25 (100) | 15 (100) | |
| yes | 1 (4) | 3 (20) | 0.1245 |
| no | 24 (96) | 12 (80) | |
| Steatosis grade | 23 (100) | 10 (100) | |
| 2/3 | 1 (4) | 0 (0) | 0.6970 |
| 0/1 | 22 (96) | 10 (100) | |
| Metavir inflammation score | 23 (100) | 12 (100) | |
| 2/3 | 0 (0) | 1 (8) | 0.3429 |
| 0/1 | 23 (100) | 11 (92) | |
| Ishak fibrosis score | 25 (100) | 14 (100) | |
| 4/5/6 | 8 (32) | 7 (50) | 0.1476 |
| 0/1/2/3 | 17 (68) | 7 (50) | |
| Child-Pugh cirrhosis score | 25 (100) | 15 (100) | |
| B/C | 4 (16) | 6 (40) | 0.0747 |
| A | 21 (84) | 9 (60) | |
| CLIP score | 25 (100) | 15 (100) | |
| 4/5/6 | 2 (8) | 0 (0) | 0.3846 |
| 0/1/2/3 | 23 (92) | 15 (100) | |
| BCLC stage | 25 (100) | 15 (100) | |
| C/D | 4 (16) | 4 (27) | 0.2245 |
| A/B | 21 (84) | 11 (73) | |
| AJCC TNM stage | 25 (100) | 15 (100) | |
| IIIA/IIIB/IIIC/IVA/IVB | 4 (16) | 5 (33) | 0.1389 |
| I/II | 21 (84) | 10 (67) |
Notes: aOnly patients with available data were analyzed. bThe percentage of pre-S2 plus pre-S1+pre-S2 deletions above 24.995 was defined as high percentage. cP-value was determined by the chi-square test. dThe density of PD-1-positive cells in tumor tissues above the median density (1.63) was defined as high density. eThe density of PD-L1-positive cells in tumor tissues above the median density (14.37) was defined as high density. fThere were no patients negative for HBsAg for analysis. *P-value<0.05; **P-value<0.01; ***P-value<0.001.
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; PD-1, programmed death 1; PD-L1, programmed death ligand 1; HBeAg, hepatitis B e antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; CLIP, Cancer of the Liver Italian Program; BCLC, Barcelona Clinic Liver Cancer; AJCC, American Joint Committee on Cancer; TNM, tumor-node-metastasis.